Numis Securities Ltd reissued their hold rating on shares of GW Pharmaceuticals plc (LON:GWP) in a research report released on Tuesday. The firm currently has a GBX 835 ($10.90) price objective on the biopharmaceutical company’s stock.

GW Pharmaceuticals plc (LON:GWP) opened at 795.00 on Tuesday. The firm’s market capitalization is GBX 2.09 billion. The company has a 50-day moving average of GBX 593.29 and a 200 day moving average of GBX 530.46. GW Pharmaceuticals plc has a one year low of GBX 211.00 and a one year high of GBX 820.00.

GW Pharmaceuticals plc Company Profile

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

Receive News & Stock Ratings for GW Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals plc and related stocks with our FREE daily email newsletter.